sitagliptin

This page shows the latest sitagliptin news and features for those working in and with pharma, biotech and healthcare.

Novo’s diabetes pill defeats Merck’s Januvia in trial

achieved the target HbA1c level – 7% or lower – compared to 28% of those treated with sitagliptin after 52 weeks of treatment. ... The drug also hit the mark in the obesity setting, with patients achieving statistically significant and superior

Latest news

FDA’s year-end approvals take annual tally to 46

Merck and Pfizer picked up an FDA approval for SGLT2 inhibitor Steglatro (ertugliflozin) and combinations Steglujan (ertugliflozin and sitagliptin) and Segluromet (ertugliflozin and metformin) for use in adults with type 2
FDA panel backs CV claims for Novo Nordisk's Victoza

Merck &Co failed to win FDA approval for a similar claim for its DPP-4 inhibitor Januvia (sitagliptin) in April.
FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying
Merck & Co and Pfizer take aim at diabetes with trio of new drugs

The marketing applications – filed in the US and EU – cover ertugliflozin as a monotherapy, a fixed-dose combination of ertugliflozin and Januvia (sitagliptin), and a fixed-dose combination of the SGLT2
EU clears AZ's FDA-rejected diabetes combination

The heart failure warning is particularly troublesome for AZ as it does not extend to Merck's top-selling DPP-4 inhibitor Januvia (sitagliptin), which is also being combined with SGLT2 ... A clean label suggests that sitagliptin/ertugliflozin will mount

More from news
Approximately 9 fully matching, plus 98 partially matching documents found.

Latest Intelligence

Market dynamics, marketing and analytics

The dotted horizontal line denotes market growth. The vertical dotted line indicates market leadership where Sitagliptin (Januvia) is the clear winner that is no longer growing at the speed of the
Interview: Christopher Boulton, AstraZeneca

sitagliptin) and Bristol-Myers Squibb (BMS), the original marketers of diabetes standard metformin under the brand name Glucophage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Senior Medical Writer, MedComms Agency: Salary TBC

Graduate Scientific Editor: DOE

Associate Scientific Director: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Medical Writer - Creative and Scientific Projects: DOE

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Manager- 4 days per week or full-time: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Account Manager: Negotiable

Market Access Consultant - Greater Manchester: Negotiable

Senior Medical Writer: Salary is DOE

Account Director, Healthcare Advertising Agency: Salary TBC

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Senior Training Manager - Surrey: Competitive Salary &Bonus

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Sudler London - Account Director: Competitive

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Subscribe to our email news alerts

PMHub

Add my company

Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....